<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019056</url>
  </required_header>
  <id_info>
    <org_study_id>MG</org_study_id>
    <nct_id>NCT02019056</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the
      Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease
      and Alcoholic Hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in AST at 14weeks</measure>
    <time_frame>14Weeks</time_frame>
    <description>To evaluate the liver function to assess improvement of the MG on change in AST lab value assessed from baseline to 12 weeks in patients with Alcoholic fatty liver disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (Safety)</measure>
    <time_frame>14weeks</time_frame>
    <description>Adverse Event: Physical examine, Lab test, Vital sign, ECG, symptom, start day and time, end day and time, severity, progress, outcome, relation with investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate ALT normalization</measure>
    <time_frame>14weeks</time_frame>
    <description>To evaluate ALT normalization assessed by comparing the percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate AST normalization</measure>
    <time_frame>14weeks</time_frame>
    <description>To evaluate AST normalization assessed by comparing the percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in AST, ALT, total lab billirubin lab value</measure>
    <time_frame>14weeks</time_frame>
    <description>To evaluate the efficacy of the MG on change in AST, ALT, total lab billirubin lab value assessed from baseline to 4, 8, 12 weeks in patients with Alcoholic fatty liver disease</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Alcoholic Fatty Liver Disease</condition>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>enteric coated capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metadoxine + garlic oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metadoxine + garlic oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metadoxine 500mg</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>enteric coated capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo /bid P.O</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG-1</intervention_name>
    <arm_group_label>MG 500mg</arm_group_label>
    <other_name>MG500mg,Placebo /bid P.O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG-2 : MG1000mg, Placebo /bid P.O</intervention_name>
    <arm_group_label>MG 1000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metadoxine</intervention_name>
    <arm_group_label>Metadoxine 500mg</arm_group_label>
    <other_name>placebo, metadoxine 500mg/ bid P.O</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢Patients over 18, under 70 years of age

               -  The chronic alcohol intake patients

                    -  Current the heavy drinker over 3month, Day the average alcohol consumption
                       Male&gt;=60g, Female&gt;=40mg y-GTP increase Male&gt;=75, Female&gt;=35

               -  Over 1.5 ratio of AST to ALT

               -  Patients who have chronoc alcohol disease

        Exclusion Criteria:

          -  Patients who have liver disease with the cause different with the alcohol except

          -  Patients who have pyridoxine allergy or history

          -  Patients who are judged by investigator that participation of the study is difficult
             due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor,
             serious metabolic disease, severe renal disease, severe pulmonary disease, severe
             cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease
             and etc

          -  Patients taking other investigational product within 90 days prior to the
             participation in the study.

          -  Patients who has been taken any medications that could affect the treatment :
             hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic acid,
             pentoxifylline, lont-term use of NSAIDs, statins, neuroleptics, anti convulsive
             medications, high-dose acetaminophen(&gt;=2.5g/day)

          -  Patients who have received treatment that may affect liver function within 1 month
             prior to the participation in the study

          -  Patient who considered ineligible for participation in the study as Investigator's
             judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanyang university Hospital</name>
      <address>
        <city>Guri city</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Fatty Liver, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metadoxine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

